Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a plasma elimination half-life of 12 hours and has been administered in a twice-daily dosing ...

Oral Factor Xa inhibitors, such as apixaban and rivaroxaban, have revolutionized anticoagulation therapy, providing effective stroke prevention and ...

Rivaroxaban is an orally active direct-acting Factor Xa inhibitor with bioavailability of more than 80%, and a predictable anticoagulant response that obviates the need for routine testing.

The FDA approved the first generics of the direct oral anticoagulant rivaroxaban ... those undergoing joint replacement ...

Dabigatran etexilate (Pradaxa; Boehringer Ingelheim) is a novel oral once-daily direct thrombin inhibitor ... to be the first once-daily oral factor Xa inhibitor to be marketed, has already ...

Factor XI Inhibitors are the alternative to DOACs, which are highly effective at preventing strokes. However, their bleeding risks often limit their use, especially in high-risk patients.

The OCEANIC-AF is comparing asundexian to Pfizer and Bristol-Myers Squibb’s widely-used oral Factor Xa inhibitor Eliquis (apixaban) in AF patients at risk of a stroke, to see how well they ...

If these new anticoagulants will fit into the current landscape, and whether they will improve clinical safety while having the same efficacy as factor Xa inhibitors, remains to be determined ...